POXEL — Poxel SA Share News
0.000.00%
Last trade - 00:00- €9.32m
- €68.25m
- €6.64m
France's Poxel Q2 revenue rises on higher TWYMEEG royalties
France's Poxel Q1 revenue rises 20% on TWYMEEG sales
Brief: Poxel Announces That A Combined General Meeting Will Be Held On December 11, 2025 And The Availability Of The Preparatory Documents
Brief: Poxel Says Cash Runway Estimated Between Mid To End Q2 2025
Brief: Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy
Brief: Poxel End-March Cash And Cash Equivalents At EUR 2.5 Million, Postpones FY Results Release
Brief: Poxel Provides Corporate Update
Brief: Poxel Reports 9-Month Revenues Of EUR 1,619 Thousand
Brief: Poxel H1 Revenue Rises To EUR 1.0 Mln
Brief: Poxel End-June Cash And Equivalents At 7.6 Mln Euros
Europe Research Roundup: Boliden AB, Fortum Oyj, Schibsted ASA
Brief: Poxel End-March Cash And Cash Equivalents At 10.6 Million Euros
RCS - Moon Surgical - Moon Surgical Appoints Anne Renevot as CFO
Brief: Poxel Announces Cash Runway Extended Through Q2 2025
Brief: Poxel FY Net Loss EUR 31.4 Mln
Brief: Poxel/PXL065: Positive Results From Phase 2 Nash Trial
Brief: Poxel Publishes In Kidney International Preclinical Results Of PXl770 In Autosomal Dominant Polycystic Kidney Disease
Brief: Poxel Reports FY Revenue Of 0.7 Mln Euros
Brief: Poxel Receives Orphan Drug Designation From EC For PXL770, PXL065